Semaglutide Weight Management (GLP-1)

The Clifford Clinic offers a medically supervised semaglutide programme for eligible adults seeking meaningful, sustained weight reduction alongside improvements in metabolic health markers. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the body's natural satiety hormone, reducing appetite, slowing gastric emptying, and improving insulin sensitivity.

The clinic follows a structured titration protocol: patients begin at 0.25mg subcutaneously once weekly for the first four weeks, stepping up to 0.5mg in weeks five to eight, before the treating physician assesses the response and determines whether to maintain or adjust the dose. This gradual start approach minimises the gastrointestinal side effects — nausea, indigestion, or reduced appetite — that are most common in the initial weeks of treatment.

Semaglutide's efficacy in clinical trials has been substantial, with participants in large phase-3 studies achieving an average body weight reduction of 15% over 68 weeks when combined with lifestyle modification. The drug also independently improves cardiovascular risk factors including blood pressure and lipid profiles, which are of particular relevance for patients whose excess weight is accompanied by metabolic syndrome.